focus -WSS

focus

author：hotspot 2025-09-27 12:58:32 - browse：23939

President Biden's White House announced the first 10 medicines that will be up first in its new drug price negotiation program. Anna Moneymaker/Getty Images

WASHINGTON — Medicare on Tuesday announced it will negotiate prices for 10 drugs, including major blood thinners and diabetes medications, in the first round of its negotiation program created in Democrats’ drug pricing reform law.

The drugs include Bristol Myers Squibb’s blood thinner Eliquis, Boehringer Ingelheim and Eli Lilly’s diabetes drug Jardiance, Johnson & Johnson’s blood thinner Xarelto, Merck’s diabetes drug Januvia, AstraZeneca’s diabetes drug Farxiga, Novartis’ heart failure treatment Entresto, Amgen’s rheumatoid arthritis drug Enbrel, Johnson & Johnson and AbbVie’s blood cancer treatment Imbruvica, J&J’s anti-inflammatory medicine Stelara, and Novo Nordisk insulins that go by names including Fiasp and NovoLog.

The new prices will be announced on Sept. 1, 2024, and will go into effect on Jan. 1, 2026. The drugs were chosen from a list of 50 treatments that cost Medicare’s pharmacy drug benefit the most money. The selected medicines cost Medicare more than $50 billion and made up 20% of the Medicare program’s pharmacy drug costs over a one-year period, the Department of Health and Human Services said. (Read more here about the winners and losers of the selection.)

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： ARCH Venture Partners tops STAT's 2023 biotech VC rankings

WSS

A public scorecard can help hold safety

Medicare to cover more brain scans for Alzheimer’s patients

A bus careens into a gulch in southern Mexico, leaving 27 people dead

AI can’t replace a physician’s gut feeling

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

Philadelphia mass shooting: Few answers in apparently random attack as suspect charged with murder

entertainment

focus

knowledge

Novavax promises a turnaround & Lilly roils the obesity market

Group opposing PBM reform sets lobbying record

How to save PrEP access — and even expand it

Group opposing PBM reform sets lobbying record

Medicare proposal to cover medical devices draws a mixed reaction

FDA approves RSV monoclonal antibody for infants, toddlers

BioMarin wins approval for gene therapy to treat hemophilia A

Princess Kate attends Wimbledon with Roger Federer: See the photos

Medicare proposal to cover medical devices draws a mixed reaction

Condition critical? Britain's beloved but battered National Health Service turns 75

entertainment

Medicare has a new plan to address drug shortages

'Insanity': 4th of July mass shootings across US kill 13, injure more than 80

In early work, researchers turn to CRISPR to treat Alzheimer's

Custom gene therapy hints at new path for rare disease treatments

EU moves toward latest gene techniques in food production to counter climate change, shortages

Startup Neumora takes a novel depression drug to Phase 3

hotspot

entertainment

Wikipedia

knowledge